And unfortunately the Juno debacle will make it MORE difficult for Prana and others to make their way through the process because the FDA will become even more cautious with the little biotechs--not wanting to be seen making the same mistake twice.
The unusual Sarepta decision earlier this year has probably made things more difficult for Prana as well because the FDA does not want to appear to have "gone soft" listening to patient advocacy groups and financially-strapped companies.
Seems like Europe is definitely the way to go.
And unfortunately the Juno debacle will make it MORE difficult...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.14M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $28.96K | 2.998M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 50 | 17608345 | 0.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.0¢ | 1358641 | 4 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| ATH (ASX) Chart |